Human malignant glioma cell lines are sensitive to low radiation doses

被引:40
作者
Beauchesne, PD
Bertrand, S
Branche, R
Linke, SP
Revel, R
Dore, JF
Pedeux, RM
机构
[1] Ctr Hosp Univ St Etienne, Serv Neurochirurg, St Etienne, France
[2] Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France
[3] NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA
关键词
radiotherapy; glioma; ultrafractionation; low-dose hypersensitivity; xenograft; ACCELERATED RADIOTHERAPY CHART; HUMAN TUMOR-CELLS; PHASE-III TRIAL; GLIOBLASTOMA-MULTIFORME; HYPERFRACTIONATED RADIOTHERAPY; INCREASED RADIORESISTANCE; MAMMALIAN-CELLS; NUDE-MICE; P53; GENE; IN-VITRO;
D O I
10.1002/ijc.11033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant gliomas display aggressive local behavior and are not cured by existing therapy. Some cell lines that are considered radioresistant respond to low radiation doses (<1 Gy) with increased cell killing (low-dose hypersensitivity). In our study, 4 of 5 human glioma cell lines exhibited significant X-ray sensitivity at doses below 1 Gy. The surviving fractions (SFs) obtained at 0.7 and/or 0.8 Gy were comparable to those at 1.5 Gy. Low-dose hypersensitivity was evident when irradiation was combined with etoposide treatment. Repeated irradiation with low doses was markedly more effective than irradiation with single, biologically equivalent doses in decreasing SFs, inhibiting xenograft tumor growth in mice. All experiments were conducted with an accelerator used in clinics, establishing that low-dose hypersensitivity was present following megavoltage X-irradiation. Thus, repeated low-dose irradiation (ultrafractionation) could greatly improve the effectiveness of radiotherapy of gliomas and could allow safe treatment of patients with cumulative doses greater than 60 Gy. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 56 条
  • [1] MUTATION AND EXPRESSION OF THE P53 GENE IN HUMAN-MALIGNANT MELANOMA
    ALBINO, AP
    VIDAL, MJ
    MCNUTT, NS
    SHEA, CR
    PRIETO, VG
    NANUS, DM
    PALMER, JM
    HAYWARD, NK
    [J]. MELANOMA RESEARCH, 1994, 4 (01) : 35 - 45
  • [2] Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas
    Beauchesne, P
    Soler, C
    Rusch, P
    Fotso, MJ
    Duthel, R
    Schmitt, T
    Brunon, J
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (03) : 210 - 216
  • [3] Beauchesne P, 2000, ANTICANCER RES, V20, P703
  • [4] Beauchesne P, 1998, CANCER CHEMOTH PHARM, V41, P93
  • [5] MEDICAL PROGRESS - BRAIN-TUMORS .1.
    BLACK, PM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) : 1471 - 1476
  • [6] Dionet C, 2000, RADIAT RES, V154, P406, DOI 10.1667/0033-7587(2000)154[0406:EOLDNA]2.0.CO
  • [7] 2
  • [8] CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY (CHART)
    DISCHE, S
    SAUNDERS, MI
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (03) : 325 - 326
  • [9] FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO
  • [10] 2-S